FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a factor Xa inhibitor salt containing a compound of structural formula I: 
and maleic acid. The invention also concerns a pharmaceutical composition, to a tablet, to a capsule, to a lozenge, to a method for preventing or treating a condition characterised by adverse thrombotic events in a mammal, to a method for inhibiting blood sample coagulation, as well as to a method for making the compound of structural formula I.
EFFECT: making the new biologically active compound for preventing or treating the condition characterised by adverse thrombotic events.
28 cl, 4 ex, 7 tbl, 6 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS | 2019 |
|
RU2813780C2 |
| STANDARD DRUG PREPARATIONS AND METHODS OF TREATING THROMBOSIS BY ORAL ADMINISTRATION OF FACTOR XA INHIBITOR | 2007 |
|
RU2452484C2 |
| BENZOATE SALT OF OTAMIXABAN | 2012 |
|
RU2597423C2 |
| CRYSTALLINE FORMS OF KNOWN PYRROLIDINE INHIBITOR OF XA FACTOR | 2006 |
|
RU2368610C2 |
| CRYSTAL FORM | 2003 |
|
RU2339634C2 |
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS | 2019 |
|
RU2817800C2 |
| THROMBOLYTIC AGENTS | 1995 |
|
RU2142799C1 |
| NOVEL CRYSTALLINE FORM OF TRIAZOLO(4,5-d)PYRIMIDINE | 2005 |
|
RU2418802C2 |
| USE OF 2-PHENYL-3-AROYLBENZOTHIOPENES FOR INHIBITION OF THROMBOTIC DISORDER AND FOR ENHANCEMENT OF PROTEIN C ACTIVATION | 1994 |
|
RU2190405C2 |
| XIa FACTOR INHIBITORS | 2016 |
|
RU2712268C2 |
